Business
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently,
About this update from Entrada Therapeutics, Inc.
[{"type":"image","alt":"Entrada Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Entrada Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/35b6e002db33bd5d921cdc15c7548cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0t5h7X6VV2P_rT4BBsLolA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0/https://media.zenfs.com/en/globenewswire.com/35b6e002db33bd5d921cdc15c7548cc1","width":300,"height":67},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0t5h7X6VV2P_rT4BBsLolA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0/https://media.zenfs.com/en/globenewswire.com/35b6e002db33bd5d921cdc15c7548cc1","width":300,"height":67}},"lazy":false},{"type":"text","content":"-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events --","length":126,"tagName":"p"},{"type":"text","content":"-- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo --","length":123,"tagName":"p"},{"type":"text","content":"-- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- ","length":232,"tagName":"p"},{"type":"text","content":"-- Consequently, Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4.00% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants --","length":192,"tagName":"p"},{"type":"text","content":"-- Statistically significant and potentially differentiated improvement in treated participants versus placebo in Time to Rise velocity, a clinically validated functional measurement --","length":185,"tagName":"p"},{"type":"text","content":"-- Company’s updated PK modeling predicts Cohort 2, building upon Cohort 1 data and combined with the recently received juvenile NHP data, will result in a significant increase of plasma AUC and substantially higher dystrophin levels with continued benefit in muscle function --","length":278,"tagName":"p"},{"type":"text","content":"-- Company has initiated dosing of ELEVATE-44-201 Cohort 2 at the increased dose of 12 mg/kg and is on track to report data by year-end 2026 --","l...